Research Signal – Source date 2026-01-28
Could creatine, an oral supplement, help prevent thinking difficulties related to chemotherapy? A ClinicalTrials.gov summary dated January 28, 2026, describes a planned comparison with placebo in people with early-stage breast cancer. It sets out how researchers intend to investigate cognitive protection during treatment and afterward; it does not establish that protection works.
The study concerns patients receiving neoadjuvant or adjuvant chemotherapy—treatment before or after surgery. Its prevention question focuses on whether supplementation can reduce the occurrence and severity of chemotherapy-related cognitive impairment, while also preserving performance on cognitive tests.
A schedule that extends into recovery
Participants are to receive oral creatine at 5 grams per day or placebo, starting seven days before chemotherapy. Supplementation is planned to continue throughout chemotherapy and until 12 months after its completion.
That schedule connects two parts of the same question. Starting before chemotherapy places the intervention ahead of the treatment period in which researchers aim to prevent cognitive difficulties. Continuing afterward extends the comparison into recovery, allowing assessments to examine cognition beyond the end of chemotherapy itself.
The end point for supplementation is therefore tied to each participant’s chemotherapy completion, rather than a fixed year from the first supplement dose. The planned exposure spans the week before treatment, the chemotherapy course and the following 12 months. This is a study regimen, not a dosing recommendation.
Two perspectives on thinking
The trial plans to collect both patient-reported cognitive assessments and objective neuropsychological tests at predefined time points. These address related questions from different perspectives.
Patient reports capture how participants experience their own cognitive function. That perspective matters because the study’s prevention goal includes the occurrence and severity of difficulties as patients perceive them. It gives participants a direct role in describing whether their thinking feels affected through treatment and recovery.
Neuropsychological testing examines performance on structured assessments. It adds a way to compare what participants can do under testing conditions with what they report about their cognition. A change in reported function and a change in test performance are distinct findings, even when both concern thinking.
Reading the two together would help clarify the nature of any difference between creatine and placebo. If the assessments point in the same direction, they could provide complementary support for an effect. If they diverge, the interpretation would need to preserve that distinction rather than compress everything into a single claim of “better cognition.”
Biological measurements and clinical follow-up
Participation also includes blood samples for biomarker analyses, stool samples for gut microbiota assessment and brain magnetic resonance imaging at selected visits. These activities broaden the investigation beyond reports and cognitive testing.
Blood and stool sampling provide material for exploratory biological analyses, while brain imaging adds another type of observation. Their role is to help researchers investigate biological context alongside cognition. A difference in a blood marker, gut microbiota measurement or scan would not, by itself, demonstrate cognitive protection or explain how creatine caused it.
Clinical follow-up has a separate purpose: assessing safety and oncologic outcomes. For a supplement intended to accompany cancer treatment, those observations are essential to interpreting any cognitive findings. The January 28 registry summary supports no conclusion about measured benefit, its size or clinical importance, safety during chemotherapy, or effects on cancer outcomes. Those conclusions require outcome evidence from the comparison.
What this could change
If the study establishes meaningful preservation of cognitive function with acceptable safety and oncologic outcomes, oral creatine could become a supportive-care option for people with early-stage breast cancer receiving chemotherapy. The practical possibility is to help patients preserve their thinking through treatment and the recovery period that follows.
Combining patients’ reports with structured testing could make that benefit more useful to interpret: it could show whether protection is experienced by patients, detected in test performance, or supported by both. That would give patients and care teams a clearer basis for discussing cognitive support within the early-stage breast cancer setting studied here.
Key Sources
- Primary source: Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment
Government or Regulator · Peer-Reviewed Paper · 2026-01-28
Keep exploring